Furthermore, immunoblot analyses confirmed that ERK1/2 activation was effectively inhibited by U0126 and showed that overexpression of GABRP enhanced ERK1/2 activation while GABRP knockdown diminished ERK1/2 activation (Figure 2d) indicating that GABRP promotes the metastatic potential of ovarian carcinoma cells through ERK pathway activation. Here, MAPK3 is linked to ovarian carcinoma.